将2020年11月—2022年5月在大理大学第一附属医院就诊的721例12种恶性肿瘤患者作为研究对象，以同期在该院体检的100例健康体检者为对照组，采集研究对象和对照组的基本信息及血清样本，ELISA检测血清中抗弓形虫IgG和IgM抗体情况, 应用SPSS 26.0软件进行数据统计分析。结果显示，721例恶性肿瘤患者中，肺癌94例、直肠癌90例、乳腺癌92例、结肠癌69例、胃癌74例、肝癌63例、甲状腺癌60例、膀胱癌40例、宫颈癌30例、宫内膜癌31例、食管癌43例及前列腺癌35例；男性418例，女性403例；平均年龄为（57.27 ± 12.23）岁；汉族361例，少数民族460例；城市324例，农村497例。恶性肿瘤患者抗弓形虫抗体阳性率为32.04%（231/721），高于对照组的13.00%（13/100）（χ² = 14.14，P ˂ 0.01），其中抗弓形虫IgG抗体阳性率（21.22%，153/721）高于对照组（8.00%，8/100）（χ² = 9.74，P ˂ 0.05），抗弓形虫IgM抗体阳性率（10.82%，78/721）与对照组（5.00%，5/100）差异无统计学意义（χ² = 2.57，P > 0.05）。肺癌、直肠癌、乳腺癌、结肠癌、胃癌、肝癌、甲状腺癌、膀胱癌、宫颈癌患者的抗弓形虫IgG抗体阳性率分别为21.28%（20/94）、22.22%（20/90）、17.39%（16/92）、26.09%（18/69）、25.68%（19/74）、19.05%（12/63）、21.67%（13/60）、25.00%（10/40）、26.67%（8/30），均高于对照组的8.00%（8/100）（χ² = 6.92、7.63、3.86、10.26、10.14、4.38、6.14、7.37、5.82，P ˂ 0.05），其余癌种的抗弓形虫IgG抗体与对照组阳性率差异均无统计学意义（P > 0.05）。乳腺癌患者的抗弓形虫IgM抗体阳性率分别为18.48%（17/92），高于对照组的5.00%（5/100）（χ² = 8.58，P ˂ 0.05），其余癌种的抗弓形虫IgM抗体与对照组阳性率差异均无统计学意义（P > 0.05）。12种不同类型恶性肿瘤患者中，以宫颈癌患者抗弓形虫IgG抗体阳性率最高，为26.67%（8/30）；以乳腺癌患者的抗弓形虫IgM抗体阳性率最高，为18.48%（17/92）；但不同癌种间抗弓形虫IgG和IgM抗体阳性率差异无统计学意义（χ² = 3.96、11.26，P > 0.05）。提示大理恶性肿瘤患者弓形虫血清阳性率高于健康人群，建议在治疗癌症的同时进行弓形虫检测。

The study included 721 patients with 12 types of malignant tumors treated at the First Affiliated Hospital of Dali University from November 2020 to May 2022 and a control group of 100 healthy individuals undergoing physical examinations during the same period. Basic information and serum samples were collected, and ELISA was used to detect the presence of anti-Toxoplasma gondii IgG and IgM antibodies in the serum samples. Statistical analysis was performed using SPSS 26.0 software. The results showed that among the 721 patients with malignant tumors, the breakdown by cancer type included lung cancer (94 cases), rectal cancer (90 cases), breast cancer (92 cases), colon cancer (69 cases), stomach cancer (74 cases), liver cancer (63 cases), thyroid cancer (60 cases), bladder cancer (40 cases), cervical cancer (30 cases), endometrial cancer (31 cases), esophageal cancer (43 cases), and prostate cancer (35 cases). There were 418 male cases and 403 female cases, with an average age of (57.27 ± 12.23) years. A total of 361 cases were of the Han ethnic group and 460 cases were of the minority group. Three hundred and twenty-four cases were from urban areas, while 497 cases were from rural areas. The positivity rate of anti-T. gondii antibodies in malignant tumor patients (32.04%, 231/721) was significantly higher than that in the control group (13.00%, 13/100) (χ² = 14.14, P ˂ 0.01). The positive rate of anti-T. gondii IgG antibodies (21.22%, 153/721) were higher than that of healthy controls (8.00%, 8/100) (χ² = 9.74, P < 0.05). There was no statistically significant difference in the positive rate of anti-T. gondii IgM antibodies (10.82%, 78/721) compared to healthy controls (5.00%, 5/100) (χ² = 2.57, P > 0.05). The positive rates of anti-T. gondii IgG antibodies in patients with lung cancer, rectal cancer, breast cancer, colon cancer, stomach cancer, liver cancer, thyroid cancer, bladder cancer, and cervical cancer were 21.28% (20/94), 22.22% (20/90), 17.39% (16/92), 26.09% (18/69), 25.68% (19/74), 19.05% (12/63), 21.67% (13/60), 25.00% (10/40), 26.67% (8/30), respectively, which were higher than those in the healthy control group of 8.00% (8/100) (χ² = 6.92, 7.63, 3.86, 10.26, 10.14, 4.38, 6.14, 7.37, 5.82; P ˂ 0.05). There was no significant difference in the positive rate of anti-T. gondii IgG antibody between other cancer types and the control group (P > 0.05). The positive rate of anti-T. gondii IgM antibodies were the highest in patients with breast cancer at 18.48% (17/92), which was significantly higher than that in the control group of 5.00% (5/100) (χ² = 8.58, P ˂ 0.05). There was no significant difference in the positive rate of anti-T. gondii IgM antibody in other types of cancer compared with the healthy control group (P > 0.05). Among 12 different types of malignant tumor patients, cervical cancer patients had the highest anti-T. gondii IgG positive rate at 26.67% (8/30). The positive rate of anti-T. gondii IgM antibody in breast cancer patients was 18.48% (17/92). However, there was no statistically significant difference in the positivity rates of anti-T. gondii IgG and IgM antibodies among different cancer (χ² = 3.96, 11.26, P > 0.05). The positive rate of T. gondii serum in patients with malignant tumors in Dali is higher than that in healthy individuals. It is recommended that T. gondii testing be conducted alongside cancer treatment.